Tandem Diabetes Care (TNDM) Hits New 52-Week High and Low at $17.64

Tandem Diabetes Care Inc (NASDAQ:TNDM)’s share price reached a new 52-week high and low during trading on Tuesday . The stock traded as low as $17.64 and last traded at $17.63, with a volume of 93439 shares changing hands. The stock had previously closed at $16.63.

Several equities analysts have commented on the stock. ValuEngine raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Saturday, April 7th. Zacks Investment Research cut shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Thursday, May 3rd. Cowen raised shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 28th. Oppenheimer set a $15.00 target price on shares of Tandem Diabetes Care and gave the company a “buy” rating in a research note on Monday, May 21st. Finally, Stifel Nicolaus reissued a “hold” rating and set a $4.00 target price on shares of Tandem Diabetes Care in a research note on Friday, March 2nd. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.32.

The company has a market capitalization of $817.61 million, a PE ratio of -1.40 and a beta of -0.10. The company has a debt-to-equity ratio of 6.45, a quick ratio of 2.01 and a current ratio of 2.62.



Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, April 26th. The medical device company reported ($1.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.44). The firm had revenue of $27.30 million for the quarter, compared to the consensus estimate of $25.32 million. Tandem Diabetes Care’s revenue was up 43.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.75) earnings per share. research analysts predict that Tandem Diabetes Care Inc will post -1.47 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Acuta Capital Partners LLC acquired a new position in shares of Tandem Diabetes Care in the 1st quarter worth approximately $6,678,000. Federated Investors Inc. PA grew its stake in shares of Tandem Diabetes Care by 714,273.3% in the 1st quarter. Federated Investors Inc. PA now owns 2,250,276 shares of the medical device company’s stock worth $11,161,000 after purchasing an additional 2,249,961 shares during the last quarter. Gabelli Funds LLC acquired a new position in shares of Tandem Diabetes Care in the 1st quarter worth approximately $102,000. Frontier Capital Management Co. LLC boosted its holdings in shares of Tandem Diabetes Care by 475.8% in the first quarter. Frontier Capital Management Co. LLC now owns 2,720,937 shares of the medical device company’s stock worth $13,496,000 after buying an additional 2,248,382 shares during the period. Finally, Westfield Capital Management Co. LP acquired a new position in shares of Tandem Diabetes Care in the first quarter worth about $378,000. 47.09% of the stock is currently owned by institutional investors.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply